Cargando…

Bringing Induced Pluripotent Stem Cell Technology to the Bedside

Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state. From a scientific perspective, their discovery has provided a molecular roadmap for turning on and off cell identities, effectively allowing any cell type to have its identity changed...

Descripción completa

Detalles Bibliográficos
Autores principales: Karagiannis, Peter, Nakauchi, Ayaka, Yamanaka, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969850/
https://www.ncbi.nlm.nih.gov/pubmed/33748517
http://dx.doi.org/10.31662/jmaj.2018-0005
_version_ 1783666313054388224
author Karagiannis, Peter
Nakauchi, Ayaka
Yamanaka, Shinya
author_facet Karagiannis, Peter
Nakauchi, Ayaka
Yamanaka, Shinya
author_sort Karagiannis, Peter
collection PubMed
description Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state. From a scientific perspective, their discovery has provided a molecular roadmap for turning on and off cell identities, effectively allowing any cell type to have its identity changed into any other cell type. They also act as a human model for understanding the development of every cell and organ in the body. In addition, because they can be prepared from patients, iPSCs offer a unique human model for studying disease development, including many diseases that are generally diagnosed at a late stage of their development. These models have provided new insights on the pathogenesis and new targets to prevent or reverse the disease development process. Indeed, clinical studies on compounds based on drug screening hits in human iPSC disease models have begun. Because of their proliferation and differentiation capacity, iPSCs can also be used to prepare cells for transplantations, and related clinical studies using iPSC-based cell therapies are ongoing. The combination of iPSCs with other technologies or therapeutic strategies is expected to expand their medical benefits. In this review, we consider medical accomplishments based on iPSC research and future ones that can be anticipated.
format Online
Article
Text
id pubmed-7969850
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Japan Medical Association
record_format MEDLINE/PubMed
spelling pubmed-79698502021-03-18 Bringing Induced Pluripotent Stem Cell Technology to the Bedside Karagiannis, Peter Nakauchi, Ayaka Yamanaka, Shinya JMA J Review Article Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state. From a scientific perspective, their discovery has provided a molecular roadmap for turning on and off cell identities, effectively allowing any cell type to have its identity changed into any other cell type. They also act as a human model for understanding the development of every cell and organ in the body. In addition, because they can be prepared from patients, iPSCs offer a unique human model for studying disease development, including many diseases that are generally diagnosed at a late stage of their development. These models have provided new insights on the pathogenesis and new targets to prevent or reverse the disease development process. Indeed, clinical studies on compounds based on drug screening hits in human iPSC disease models have begun. Because of their proliferation and differentiation capacity, iPSCs can also be used to prepare cells for transplantations, and related clinical studies using iPSC-based cell therapies are ongoing. The combination of iPSCs with other technologies or therapeutic strategies is expected to expand their medical benefits. In this review, we consider medical accomplishments based on iPSC research and future ones that can be anticipated. Japan Medical Association 2018-09-28 2018-09-28 /pmc/articles/PMC7969850/ /pubmed/33748517 http://dx.doi.org/10.31662/jmaj.2018-0005 Text en Copyright © Japan Medical Association http://creativecommons.org/licenses/by/4.0/ JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Karagiannis, Peter
Nakauchi, Ayaka
Yamanaka, Shinya
Bringing Induced Pluripotent Stem Cell Technology to the Bedside
title Bringing Induced Pluripotent Stem Cell Technology to the Bedside
title_full Bringing Induced Pluripotent Stem Cell Technology to the Bedside
title_fullStr Bringing Induced Pluripotent Stem Cell Technology to the Bedside
title_full_unstemmed Bringing Induced Pluripotent Stem Cell Technology to the Bedside
title_short Bringing Induced Pluripotent Stem Cell Technology to the Bedside
title_sort bringing induced pluripotent stem cell technology to the bedside
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969850/
https://www.ncbi.nlm.nih.gov/pubmed/33748517
http://dx.doi.org/10.31662/jmaj.2018-0005
work_keys_str_mv AT karagiannispeter bringinginducedpluripotentstemcelltechnologytothebedside
AT nakauchiayaka bringinginducedpluripotentstemcelltechnologytothebedside
AT yamanakashinya bringinginducedpluripotentstemcelltechnologytothebedside